ART BioScience
PrivateLast Round
Series B
Jul 29, 2025
Total Funding Raised
$245M
Company Overview
ART BioScience operates in Healthcare & Life Sciences and is based in Israel. Its latest recorded funding round was a Series B round in July 2025.
ART BioScience is a biotechnology company that develops mRNA-based therapeutics and gene-editing therapies for the treatment of Duchenne muscular dystrophy and other rare genetic disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ART BioScience Comparables
Compare ART BioScience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Spot Biosystems | 82% | |
| MyoGene Bio | 77% | |
| Entrada Therapeutics | 70% |
For institutional investors. Book with your work email.
ART BioScience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 29, 2025 | ||||
| Series A | Dec 7, 2023 | ||||
| Seed | Jun 1, 2023 |
For institutional investors. Book with your work email.
ART BioScience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Omega Funds | Series A, Series B, Seed |
| B Capital Group | Series B |
| Alexandria Venture Investments | Series B |
| F-Prime Capital | Series A, Series B, Seed |
| Sofinnova Investments | Series B |
| Qatar Investment Authority | Series B |
| Third Rock Ventures | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2025
$132M round led by B Capital Group and Sofinnova Investments.
- Dec 7, 2023
$90M round led by Third Rock Ventures
For institutional investors. Book with your work email.
ART BioScience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ART BioScience's valuation, stock price, and market status.
Is ART BioScience a public or private company?
ART BioScience is a private company.
What is the current stock price of ART BioScience?
ART BioScience is a private company, so its shares have no public market price. Caplight tracks ART BioScience's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ART BioScience worth (valuation)?
Valuation information for ART BioScience is not publicly available.
Can I buy ART BioScience stock?
ART BioScience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ART BioScience's last funding round?
ART BioScience's most recent funding round was Series B on July 29, 2025.
Who are the main investors in ART BioScience?
Key investors in ART BioScience include Omega Funds, B Capital Group, F-Prime Capital, Sofinnova Investments, Third Rock Ventures.
Will ART BioScience IPO soon?
No public IPO plans have been announced for ART BioScience.
How can I track ART BioScience secondary market activity?
Caplight tracks bids, offers, and trades in ART BioScience's shares on secondary markets.